Inhibikase adds Amgen vet Scott Wasserman to board; Dennis Berman resigns

Inhibikase Therapeutics, Inc.

Scott M. Wasserman, MD, appointed Class III director effective October 19, 2026, serving until the 2029 annual meeting; he joins the Compensation Committee.
Wasserman gets an initial grant of non-qualified options for up to 310,000 IKT shares plus cash compensation under the non-employee director policy.
Wasserman is CMO of Kailera Therapeutics; at Amgen he led global development and approvals of Repatha, Evenity and Aimovig.
Dennis Berman resigned the same day as director and Compensation Committee chair and Audit Committee member; no disagreement cited.
Chairman Amit Munshi cited Wasserman's expertise as Inhibikase advances the global Phase 3 IMPROVE-PAH study of oral IKT-001 for PAH.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Scott Wasserman

Class III director

IKT · Inhibikase Therapeutics, Inc.

Effective: 2026-10-19
Filed: October 20, 2026, 4:57 PM ET

On October 19, 2026, the Board, upon the recommendation of the Board’s Corporate Governance and Nominating Committee, appointed Scott Wasserman to serve as a Class III director, to hold office until the Company’s annual meeting of stockholders in 2029 or until his earlier death, resignation or removal, effective as of October 19, 2026 (the “Appointment Date”).

Departed

Dennis Berman

Director; Chair of the Compensation Committee; member of the Audit Committee

IKT · Inhibikase Therapeutics, Inc.

Effective: 2026-10-19
Filed: October 20, 2026, 4:57 PM ET

On October 19, 2026, Dennis Berman resigned from the board of directors (the “Board”) of Inhibikase Therapeutics, Inc. (the “Company”) and his position as Chair of the Compensation Committee of the Board (the “Compensation Committee”) and a member of the Audit Committee of the Board (the “Audit Committee”), effective as of October 19, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Wasserman was appointed as Class III director at Inhibikase Therapeutics, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

On October 19, 2026, the Board, upon the recommendation of the Board’s Corporate Governance and Nominating Committee, appointed Scott Wasserman to serve as a Class III director, to hold office until the Company’s annual meeting of stockholders in 2029 or until his earlier death, resignation or removal, effective as of October 19, 2026 (the “Appointment Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dennis Berman resigned as Director; Chair of the Compensation Committee; member of the Audit Committee at Inhibikase Therapeutics, Inc..

Action: resigned
Role: Director; Chair of the Compensation Committee; member of the Audit Committee

Exact text from the filing

On October 19, 2026, Dennis Berman resigned from the board of directors (the “Board”) of Inhibikase Therapeutics, Inc. (the “Company”) and his position as Chair of the Compensation Committee of the Board (the “Compensation Committee”) and a member of the Audit Committee of the Board (the “Audit Committee”), effective as of October 19, 2026.

View on SEC.gov

Inhibikase Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-426811

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.